Get started
Sage Therapeutics, Inc.Sage Therapeutics, Inc.Sage Therapeutics, Inc.

Sage Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

SAGE trade ideas

SAGE-217 Post Partum DepressionSo What? SAGE has been on its own phase the last 2 trading days. Jan 7 - announced Phase 3 success of SAGE-217 for postpartum depression; same day AXS-05 for MDD was reported. Both drugs are being compared to each other for the future MDD treatment; promising (as usual). Axsome is a low hanging fruit with a higher volume but I do like how SAGE moves. I'll have to see this through. Short float is at 7.78%, need more volume. Word is, there is a "little innovation" nowadays when it comes to CNS disorders like depression, which makes SAGE-217 is worth the watch.
NASDAQ:SAGELong
by UnknownUnicorn2993086
SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 ClinicAbout the ROBIN Study Sage’s Phase 3 ROBIN Study evaluated the efficacy, safety and pharmacokinetics of SAGE-217 in 151 adult female patients diagnosed with severe postpartum depression (PPD). The primary endpoint of the multicenter, randomized, double-blind, parallel-group, placebo-controlled study was to determine if outpatient treatment with SAGE-217 reduces depressive symptoms in subjects with severe PPD compared to placebo as assessed by the change from baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score at Day 15. investor.sagerx.com
NASDAQ:SAGE
by AlenCiken
Ready to climbWell this baby is ready to go higher, it is making higher lows and seems very well consolidated. There is an FDA report for an expedite development of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217. This would be the final phase of trials before receiving the right to file a New Drug Application with the FDA and potentially market the drug early next year. SAGE is focused on the development of products for the treatment of life-threatening central nervous system disorders. As of now, there are two products under development based on the NMDA (N-methyl-D-aspartate) receptor program: SAGE-718 and SAGE-904. It looks like a good to go for the rest of the year, be ready to get out at +30% - +40%
NASDAQ:SAGELong
by TotalBitcoinInternational
1